Table of contents

  • Preliminary material
    • Title and verso page
    • Contents
    • Acknowledgments
    • Summary
      • What was the financial cost of DMARD treatment through the PBS?
      • What DMARDs were supplied?
      • Who was supplied with DMARDs?
      • Who were the DMARD prescribers?
      • Does starting treatment with bDMARDs change the supply of conventional DMARDs?
  • Body section
    • 1 Introduction
      • What is rheumatoid arthritis?
        • Classification criteria for rheumatoid arthritis
      • What are DMARDs?
      • Extent of need
        • General practitioner (GP) consultations
      • Treatment of rheumatoid arthritis
      • Rheumatoid arthritis and DMARDs
      • DMARDs on the PBS
      • Structure of the report
    • 2 Data source and methodology
      • Pharmaceutical Benefits Scheme
      • The data extract
        • Data items
        • Record selection
        • Population subgroups
          • Remoteness
          • Socioeconomic status
        • Completeness of the supply of DMARD data
    • 3 Supply of DMARDs on the PBS
      • Conventional DMARDs on the PBS
      • Prescribers
      • Conventional DMARD users
        • Socioeconomic profile
        • Regional profile
      • bDMARDs on the PBS
        • bDMARD users
      • Disease prevalence and DMARD prescriptions
    • 4 bDMARD treatment pathways
      • The bDMARD cohort
      • The first bDMARD
      • Conventional DMARDs before the supply of bDMARDs
      • Supply of conventional DMARDs following the initiation of bDMARD therapy
    • 5 PBS subsidy for DMARDs
      • Overall expenditure
      • Expenditure on conventional DMARDs
      • Expenditure on bDMARDs
    • 6 Discussion
      • Key findings
      • Notes on the data
  • End matter
    • Appendix A: DMARD treatment pathways
    • Appendix B: DMARDs on the PBS, 2003-2007
    • Appendix C: PBS data and codes
    • References